Veradigm vs ResMed

Side-by-side comparison of AI visibility scores, market position, and capabilities

ResMed leads in AI visibility (91 vs 63)
Veradigm logo

Veradigm

ChallengerHealthcare

EHR/Data Solutions

Healthcare data company with 130K connected physicians; EHR-connected real-world evidence network for pharma analytics rebranded from Allscripts competing with IQVIA for life sciences data.

AI VisibilityBeta
Overall Score
B63
Category Rank
#1 of 1
AI Consensus
75%
Trend
up
Per Platform
ChatGPT
70
Perplexity
61
Gemini
60

About

Veradigm (formerly Allscripts Healthcare) is a healthcare information technology company providing EHR-connected data network services, physician practice management software, pharmacy solutions, and life sciences data analytics — operating at the intersection of clinical care delivery and healthcare data commercialization. Listed on NASDAQ (NASDAQ: MDRX) and headquartered in Chicago, Illinois, Veradigm rebranded from Allscripts in 2023 as it refocused from clinical EHR software toward data and analytics services, generating approximately $600 million in annual revenue.\n\nVeradigm's core asset is its network of approximately 130,000 connected physicians and tens of millions of de-identified patient records accessible through its data products. The Veradigm Network connects ambulatory physician practices running Allscripts EHR (Professional EHR, TouchWorks) and enables data flows for prescription analytics, clinical decision support, and real-world evidence (RWE) for pharmaceutical companies. The life sciences data business provides pharma clients with prescription analytics, patient journey data, and clinical research data services.\n\nIn 2025, Veradigm is in strategic transition — the company has been exploring alternatives to maximize shareholder value, including potential sale or acquisition, following activist investor pressure. The EHR product portfolio (Allscripts-branded physician practice software) competes with athenahealth, Epic, and eClinicalWorks in the ambulatory market, though Veradigm's focus has shifted toward its data network value rather than competing head-to-head in EHR functionality. Veradigm competes with IQVIA, Komodo Health, and Definitive Healthcare for life sciences real-world data. The 2025 strategy focuses on growing the data analytics and real-world evidence business while managing the legacy EHR product base.

Full profile
ResMed logo

ResMed

LeaderHealthcare Tech

Sleep & Respiratory Devices

ResMed (RMD) reported ~$4.7B revenue in FY2024. Global leader in cloud-connected devices for sleep apnea, COPD, and out-of-hospital care, with 10M+ connected devices. HQ: San Diego.

AI VisibilityBeta
Overall Score
A91
Category Rank
#1 of 1
AI Consensus
95%
Trend
up
Per Platform
ChatGPT
88
Perplexity
89
Gemini
89

About

ResMed Inc. is the global leader in cloud-connected medical devices and software for diagnosing and treating sleep apnea, chronic obstructive pulmonary disease (COPD), and other respiratory conditions in out-of-hospital settings. Founded in Sydney, Australia in 1989, the company designs and manufactures CPAP (continuous positive airway pressure) machines, masks, ventilators, and related accessories used by patients with obstructive sleep apnea — a condition affecting approximately 1 billion people globally that is chronically under-diagnosed and under-treated.

Full profile

AI Visibility Head-to-Head

63
Overall Score
91
#1
Category Rank
#1
75
AI Consensus
95
up
Trend
up
70
ChatGPT
88
61
Perplexity
89
60
Gemini
89
61
Claude
90
64
Grok
88

Key Details

Category
EHR/Data Solutions
Sleep & Respiratory Devices
Tier
Challenger
Leader
Entity Type
company
company

Capabilities & Ecosystem

Capabilities

Only Veradigm
EHR/Data Solutions
Only ResMed
Sleep & Respiratory Devices
Veradigm is classified as company. ResMed is classified as company.

Track AI Visibility in Real Time

Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.